Please assess the completion status of the following clinical trial:

Trial Title: Heterologous Effects of BCG in Healthy UK Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Volunteers must meet all of the following criteria to enter the study:~* Healthy adult aged 18-45 years~* BCG naïve~* Resident in or near Oxford (for CCTVM and John Warin Ward) or Birmingham (for NIHR WTCRF) for the duration of the study period~* No relevant findings in medical history or on physical examination~* Allow the Investigators to discuss the volunteer's medical history with their GP~* Use effective contraception for the duration of the study period (females only)~* Agreement to refrain from blood donation during the duration of the study and for a period of 3 months after their last visit~* Give written informed consent~* Allow the Investigator to register volunteer details with a confidential database to prevent concurrent entry into clinical trials or studies~* Able and willing (in the Investigator's opinion) to comply with all the study requirements~Exclusion Criteria:~Volunteers must meet none of the following criteria to enter the study:~* Laboratory evidence at screening of latent M. tb infection as indicated by a positive IGRA response~* Clinical, radiological, or laboratory evidence of current active TB disease~* Previous vaccination with BCG, or any candidate TB vaccine~* Within the last year had close household contact with an individual with smear positive pulmonary tuberculosis~* Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse~* History of serious psychiatric condition~* Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents~* Concurrent use of long term antibiotic therapy~* History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the BCG vaccine~* Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the volunteer in the study~* Positive HBsAg, HCV or HIV antibodies~* Female confirmed pregnant or intention to become pregnant during study period, or currently lactating~* Current involvement in another study or trial that involves regular blood tests or an investigational medicinal product~* Use of an investigational medicinal product or non-registered drug, live vaccine, or investigational medical device for four weeks prior to dosing with the study vaccine~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned challenge date~* Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, or may influence the result of the study, or may affect the volunteer's ability to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10\^5 cfu) via Intradermal route.
- Group 2 (Type: EXPERIMENTAL): 8-16 control volunteers receiving no vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete